On June 11, 2018 Nordic Nanovector ASA (OSE: NANO) reported that a poster reporting the ability of Betalutin (177Lu-lilotomab satetraxetan) to reverse resistance to anti-CD20 treatment in non-Hodgkin’s lymphoma (NHL) cell lines will be presented at the inaugural AACR (Free AACR Whitepaper) International Meeting: Advances in Malignant Lymphoma (22-26 June, Boston, MA, USA) (Press release, Nordic Nanovector, JUN 11, 2018, View Source [SID1234553500]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The preclinical data, described in an abstract published online (link here), demonstrate that treatment of rituximab-resistant NHL cells with Betalutin significantly elevated the expression of the CD20 receptor on the surface of cells. The increase in CD20 receptors re-sensitizes the cells to the anti-CD20 NHL immunotherapies rituximab (Rituxan) and obinutuzumab (Gazyva/Gazyvaro), causing increased tumour cell death.
These results support previous preclinical studies that highlight the synergistic anti-tumour effects of combining Betalutin with rituximab immunotherapy. Nordic Nanovector is planning to investigate this novel combination therapy in patients with relapsed/refractory follicular lymphoma in the Archer-1 Phase 1b clinical study. This study is targeting dosing of the first patient in the second half of 2018.
Details for the poster presentation are as follows:
Poster Title: 177Lu-lilotomab satetraxetan has the potential to counteract resistance to rituximab and obinutuzumab in non-Hodgkin’s lymphoma Session
Date and Time: Saturday 23 June, 11:45 AM to 1:45 PM (Eastern Daylight Time)
Poster Session A: Basic and Translational Science 1
Location: Salon F, 4th floor, Boston Marriot Copley Plaza Permanent
Abstract Number: A28
The poster will be available on the company’s website at the time of the presentation: www.nordicnanovector.com.